NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024

April 24, 2024

https://www.globenewswire.com/news-release/2024/04/24/2869062/0/en/NextCure-to-Present-Phase-1b-Data-of-NC410-in-Combination-with-Pembrolizumab-at-ASCO-2024.html

BELTSVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) —  NextCure, Inc. (Nasdaq:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical trial investigator Eric S. Christenson, M.D., Assistant Professor of Oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, will present a poster on clinical data from the Phase 1b portion of a study evaluating NC410 in combination with pembrolizumab at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 – June 4 in Chicago.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.